Company Name: Protalix BioTherapeutics, Inc.

Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The company uses its proprietary ProCellEx® plant cell-based protein expression system to develop recombinant therapeutic proteins. The company’s first commercial product is a long-term enzyme replacement therapy for adult patients with a confirmed diagnosis of Type 1 Gaucher disease.

Ticker Symbol: PLX (AMEX)

Company Website: www.protalix.com

Social Media: Protalix BioTherapeutics LinkedIn

Headquarters: Carmiel, Israel